Law360, New York (May 12, 2011, 9:19 PM ET) -- The Delaware federal judge overseeing multidistrict litigation over Cephalon Inc.'s Amrix drug ruled Tuesday that Mylan Pharmaceuticals Inc. and Barr Laboratories Inc. infringed two patents covering the muscle relaxant, but also said the patents-in-suit were invalid for being obvious.
U.S. District Judge Sue L. Robinson also determined that Anchen Pharmaceuticals Inc. did not infringe the patents-in-suit, which describe methods for delivering an extended dosage of cyclobenzaprine hydrochloride, the active ingredient in Amrix.
The MDL consolidates six cases Cephalon launched to block generic makers from making versions...
Cephalon's Amrix IP Invalid, Infringed: Judge
To view the full article, take a free trial now.
